2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Chuong discusses the evolution of MRI-guided radiation in the cancer treatment armamentarium, the benefits of the MRIdian SMART system, and how Miami Cancer Institute is leading the way with trainings to expand the use of this technology.
Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Michael D. Chuong, MD, who joined us to discuss the use of magnetic resonance imaging (MRI)–guided radiation therapy in patients with cancer. Dr Chuong is the vice chair and medical director of Radiation Oncology and leader of the GI Radiation Service at Baptist Health Miami Cancer Institute in Florida.
The phase 2 SMART trial (NCT03621644) investigated 5-fraction stereotactic magnetic resonance–guided on-table adaptive radiation therapy (SMART) in patients with borderline resectable or locally advanced pancreatic cancer. In total, 8.8% of patients experienced acute gastrointestinal toxicities of grade 3 or higher that were possibly related to SMART. The 1-year overall survival rate after SMART was 65.0%.
Supported by the SMART trial findings, the LAP-ABLATE trial (NCT05585554) will evaluate the efficacy and safety of induction chemotherapy followed by SMART vs chemotherapy alone in patients with locally advanced pancreatic cancer.
In our exclusive interview, Dr Chuong discussed the evolution of MRI-guided radiation in the cancer treatment armamentarium, the benefits of the MRIdian SMART system, and how Miami Cancer Institute is leading the way with trainings to expand the use of this technology.
___
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
Related Content: